>98%
Purity HPLC
COA
Every batch
EU
Fulfilment
Discreet
Shipping
GLP-3R acts as a simultaneous agonist at three distinct metabolic receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triple mechanism distinguishes it from dual or single receptor agonists and has produced compelling data in early research.
The GLP-1 component drives insulin secretion and appetite suppression; the GIP component enhances insulin response and may reduce the nausea associated with GLP1 mono-agonism; the glucagon component increases energy expenditure and hepatic fat mobilisation. Together these mechanisms produce a complementary and potent metabolic profile in research models.
Phase 1 and Phase 2 clinical data have demonstrated substantial effects on body weight reduction and metabolic markers, positioning GLP-3R among the most actively researched compounds in metabolic science.
Key research areas include:
– Triple GIP/GLP-1/glucagon receptor agonism
– Body weight regulation and adipose reduction
– Insulin secretion and glucose metabolism
– Hepatic lipid metabolism
– Energy expenditure modulation
– Appetite and satiety signalling
- Triple Receptor Agonism
GLP-3R’s simultaneous activation of GIPR, GLP-1R, and GCGR produces complementary metabolic effects that address multiple pathways simultaneously. The glucagon component in particular adds energy expenditure benefits not seen with dual GLP1/GIP agonists. - Appetite & Satiety Regulation
GLP-1R agonism drives significant reductions in appetite through central and peripheral mechanisms, including slowing of gastric emptying and direct hypothalamic signalling. Research has consistently documented reductions in caloric intake in relevant models. - Glucose Metabolism
The GIP and GLP-1 components both contribute to glucose-dependent insulin secretion, improving glycaemic control without hypoglycaemic risk at physiological glucose concentrations. - Hepatic Lipid Metabolism
Glucagon receptor activation promotes hepatic fat oxidation and reduces lipogenesis, making GLP-3R of particular interest in models of hepatic steatosis and metabolic dysfunction. - Body Composition
Early clinical data have documented substantial reductions in body weight and improvements in lean-to-fat ratios, with effects exceeding those of GLP-1 monoagonists in comparative research.
Key References:
– Coskun T et al. Retatrutide (LY3437943), a GIP, GLP-1, and glucagon receptor agonist. Cell Metab. 2022.
– Jastreboff AM et al. Triple hormone receptor agonist retatrutide for obesity. N Engl J Med. 2023.
– Finan B et al. Unimolecular dual incretins maximize metabolic benefits. Sci Transl Med. 2013.- Triple Receptor Agonism
| Parameter | Detail |
| Peptide | GLP-3R (Triple GIP/GLP-1/GCG Receptor Agonist) |
| Molecular Weight | 5767.49 g/mol |
| CAS Number | 2381089-83-2 |
| Appearance | White lyophilised powder |
| Purity | >99% (HPLC) |
| Vial Size | 10mg |
| Storage | -20°C, protect from light and moisture |
| Reconstitution | Bacteriostatic water or sterile saline |
| Shelf Life | 24 months (lyophilised) / 30 days (reconstituted, refrigerated) |
| Format | Lyophilised powder, single-use research vial |
Reviews
There are no reviews yet.